Content of N2 Bulletin, 2012

REGULATORY NEWS

- Definition of international standarts of medicines
- EMA: new aliskiren restrictions
- Aprotinin gets green light
- Orlistat benefits worth the risks
- Important safety label changes to cholesterol-lowering statin drugs
- Fenofibric acid. Lable change.
- Skin creams, soaps and lotions marketed as skin lighteners and anti-aging treatments: may contain the toxic metal, mercury
- Updated information about the risk of blood clots in women taking birth control pills containing drospirenone Fluoroquinolone. Patients with myasthenia gravis may risk increased muscle weakness
- Pioglitazone. An increased risk of bladder cancer.
- Simvastatin with amiodarone: dosage review

DRUGS SAFETY

- A little about the cost of medical mistakes
- Proton pump inhibitors. Reports of acute renal reactions, primarily interstitial nephritis
- Montelukast: psychiatric disorders
- Varenicline: long-term cardiovascular events
- Ursodeoxycholic acid: serious hepatic events
- Drug-induced weight gain
- Quetiapine: information updated

LEVIDENCE BASED MEDICINE

- Anticancer therapy makes the cancer more aggressive and deadly dangerous
- Chemotherapy can lead to the regrowth of cancer
- Preoperative skin antiseprics: clinical advantage with chlohexidine
- Inhibition of lactation: risks associated with dopamine agonists

♣ FOR PHYSICIANS (SPECIALISTS)

Drug interactions with herbal products and dietary supplements

UR PUBLICATIONS

The Human Genome: unfulfilled dreams or new ways? R.Sh.Mathevosyan, A.A.Engibaryan

♣ FOR GENERAL PHYSICIANS

- Quaternary prevention: a task of the general practitioner
- Analgesics and pain relief in pregnancy and breastfeeding
- Preventing early neonatal Group B streptococcal disease

SCIENTIFIC PUBLICATION

Neurogenesis - the birth of new neurons. R.Mathevosyan, A.Ayvazyan